公开(公告)号：US12098390B2

公开(公告)日：2024-09-24

申请号：US17403202

申请日：2021-08-16

Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION

Inventor： Igor Slukvin ,  Akhilesh Kumar

IPC: C12N5/077 ,  A61K35/34 ,  A61K35/44 ,  A61K35/28

CPC classification number: C12N5/0661 ,  A61K35/34 ,  A61K35/44 ,  A61K35/28 ,  C12N2500/90 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/135 ,  C12N2501/15 ,  C12N2501/165 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/1346 ,  C12N2506/45

Abstract: The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitors, and methods and compositions for clinical applications in the field of regenerative medicine.

公开(公告)号：US20240271097A1

公开(公告)日：2024-08-15

申请号：US18568172

申请日：2022-06-08

Applicant: Sanford Burnham Prebys Medical Discovery Institute

Inventor： Alexandre COLAS ,  Maria Azzurra MISSINATO ,  Michael S. YU

IPC: C12N5/077 ,  A61K35/30 ,  A61K35/34 ,  C12N5/0793 ,  C12N15/113

CPC classification number: C12N5/0657 ,  A61K35/30 ,  A61K35/34 ,  C12N5/0619 ,  C12N15/113 ,  C12N2310/14 ,  C12N2501/999 ,  C12N2506/1307 ,  C12N2506/28 ,  C12N2510/00

Abstract: This present disclosure provides methods and pharmaceutical compositions for cell reprogramming and a pharmaceutical composition comprising the reprogrammed cells. In certain embodiments, the method of reprogramming a cell comprises reducing the expression of at least one barrier gene selected from the group consisting of ATF7IP, JUNB, ZNF207, Sp7, FOXA1, HEXIM2, SMARCA5, SOX15, CHST2 or NCEH1, or if the barrier gene is ATF7IP or SOX15, then the expression of a second barrier gene is also reduced. In another embodiment, the reprogramming method comprises reducing the expression of at least two barrier genes selected from the group consisting of ATF7IP, JUNB, ZNF207 and Sp7.

公开(公告)号：US12042381B2

公开(公告)日：2024-07-23

申请号：US16677323

申请日：2019-11-07

Applicant: UNIVERSITATSKLINIKUM HAMBURG-EPPENDORF

Inventor： Wolfram-Hubertus Zimmermann ,  Thomas Eschenhagen ,  Yalin Yildirim

IPC: A61L27/38 ,  A61F2/24 ,  A61K35/34 ,  A61L27/54

CPC classification number: A61F2/2481 ,  A61K35/34 ,  A61L27/38 ,  A61L27/54 ,  A61F2240/001 ,  A61L2300/412 ,  A61L2300/414

Abstract: The invention is directed to a pouch-like construct comprising mammalian tissue which can be used for preventing distension and/or resisting dilation of the heart in a mammal. Preferably, the pouch-like tissue construct has contractile properties. The invention further relates to a method for the preparation of a pouch-like construct comprising mammalian tissue which can be used for the above purposes.

公开(公告)号：US20240122990A1

公开(公告)日：2024-04-18

申请号：US18278085

申请日：2022-02-22

Applicant: UNIVERSITY OF WASHINGTON

Inventor： Charles E. MURRY ,  William Robb MACLELLAN ,  Robert Scott THIES ,  Kenta NAKAMURA ,  Daisy Sue NAKAMURA ,  Lauren E. NEIDIG

IPC: A61K35/34 ,  A61K31/436 ,  A61K38/17 ,  A61P37/06

CPC classification number: A61K35/34 ,  A61K31/436 ,  A61K38/1774 ,  A61P37/06

Abstract: The present disclosure provides for the treatment of cardiac diseases and disorders using in vitro-differentiated cardiomyocytes. Such methods can take advantage of both autologous and allogeneic pluripotent stem cells.

公开(公告)号：US20240043867A1

公开(公告)日：2024-02-08

申请号：US18058283

申请日：2022-11-23

Applicant: GENETHON ,  SORBONNE UNIVERSITE

Inventor： FEDERICO MINGOZZI ,  GIUSEPPE RONZITTI ,  PASQUALINA COLELLA ,  FRANCESCO PUZZO

IPC: C12N15/86 ,  A61K35/34 ,  A61K35/407

CPC classification number: C12N15/86 ,  A61K35/34 ,  A61K35/407 ,  C12N2510/00 ,  C12N2750/14143 ,  C12Y302/0102

Abstract: The present invention relates to variants of acid-alpha glucosidase and uses thereof.

公开(公告)号：US20230416413A1

公开(公告)日：2023-12-28

申请号：US18459892

申请日：2023-09-01

Applicant: Children's Medical Center Corporation ,  Beth Israel Deaconess Medical Center, Inc.

Inventor： James D. McCully ,  Sidney Levitsky ,  Douglas B. Cowan ,  Pedro J. del Nido ,  Sitaram M. Emani

IPC: C07K16/46 ,  A61K35/12 ,  A61K49/00 ,  A61K49/18 ,  A61K51/04 ,  A61K51/12 ,  A61K35/28 ,  A61K35/34 ,  A61K47/69 ,  A61K9/00 ,  A61B6/00 ,  C12N15/11

CPC classification number: C07K16/468 ,  A61B8/0883 ,  A61K49/0002 ,  A61K49/1821 ,  A61K49/1896 ,  A61K51/0421 ,  A61K51/1203 ,  A61K35/28 ,  A61K35/34 ,  A61K47/6901 ,  A61K9/0019 ,  A61B6/42 ,  A61K51/1282 ,  C12N15/11 ,  A61B6/503 ,  A61K35/12

Abstract: The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.

公开(公告)号：US11773408B2

公开(公告)日：2023-10-03

申请号：US16707223

申请日：2019-12-09

Applicant: Lucie Carrier ,  Thomas Eschenhagen ,  Thomas Voit ,  Giulia Mearini ,  Oliver Mueller ,  Doreen Stimpel

Inventor： Lucie Carrier ,  Thomas Eschenhagen ,  Thomas Voit ,  Giulia Mearini ,  Oliver Mueller ,  Doreen Stimpel ,  Julia Mourot-Filiatre

IPC: C12N15/86 ,  C07K14/47 ,  A61K35/34 ,  C12N5/074 ,  C12N5/077 ,  A61K48/00 ,  C12N7/00

CPC classification number: C12N15/86 ,  A61K35/34 ,  A61K48/0058 ,  C07K14/4716 ,  C12N5/0657 ,  C12N5/0696 ,  C12N7/00 ,  C12N2506/45 ,  C12N2750/14143 ,  C12N2799/025 ,  C12N2830/007 ,  C12N2830/008

Abstract: The present invention relates to a gene therapy vector which is useful in the treatment or prevention of hypertrophic cardiomyopathy in a subject in need thereof. The gene therapy vector of the invention comprises a nucleic acid sequence encoding a cardiac sarcomeric protein and a cardiomyocyte-specific promoter which is operably linked to said nucleic acid sequence. The invention furthermore relates to a cell which comprises the gene therapy vector. Pharmaceutical compositions which comprise the gene therapy vector and/or a cell comprising said vector are also provided. In another aspect, the invention relates to a method for treating or preventing hypertrophic cardiomyopathy in a subject by introducing the gene therapy vector of the invention into a subject in need of treatment.

公开(公告)号：US20230293596A1

公开(公告)日：2023-09-21

申请号：US18114861

申请日：2023-02-27

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Marco Quarta ,  Thomas A. Rando

IPC: A61K35/34 ,  C12N5/077

CPC classification number: A61K35/34 ,  C12N5/0658 ,  C12N2500/90 ,  C12N2510/00 ,  C12N2500/25 ,  C12N2501/34 ,  C12N2501/999 ,  C12N2501/15

Abstract: Compositions and methods are provided for induction and maintenance of quiescence of stem cells.

公开(公告)号：US20230256024A1

公开(公告)日：2023-08-17

申请号：US18014201

申请日：2021-07-13

Applicant: KYOTO UNIVERSITY ,  ASAHI KASEI KABUSHIKI KAISHA

Inventor： Hidetoshi SAKURAI ,  Mingming ZHAO ,  Hiroki KATO ,  Atsutoshi TAZUMI

IPC: A61K35/34 ,  C12N5/077

CPC classification number: A61K35/34 ,  C12N5/0658 ,  C12N2500/25 ,  C12N2501/12 ,  C12N2501/105 ,  C12N2501/115 ,  C12N2506/45

Abstract: The present invention provides a composition that is for treating myogenic diseases and that contains a cell group including skeletal muscle precursor cells differentiation-induced from pluripotent stem cells, the composition being characterized in that the cell group includes the skeletal muscle precursor cells that are Pax7-positive, and are CD146 (MCAM)-positive and CD57-negative on the surface thereof. The present invention also provides a method for purifying skeletal muscle precursor cells.

公开(公告)号：US11684574B2

公开(公告)日：2023-06-27

申请号：US16308889

申请日：2017-06-29

Applicant: University of Pittsburgh—Of the Commonwealth System of Higher Education

Inventor： Morgan Virginia Fedorchak ,  Jeffrey Krawiec ,  Steven R. Little ,  Katherine Lorentz ,  David A. Vorp ,  Justin Weinbaum

IPC: A61L27/50 ,  A61L27/56 ,  A61L27/58 ,  A61K9/107 ,  A61K9/00 ,  A61K9/16 ,  A61K35/15 ,  A61K35/28 ,  A61K35/34 ,  A61K35/39 ,  C12N5/071

CPC classification number: A61K9/1075 ,  A61K9/0004 ,  A61K9/1647 ,  A61K35/15 ,  A61K35/28 ,  A61K35/34 ,  A61K35/39 ,  A61L27/507 ,  A61L27/56 ,  A61L27/58 ,  C12N5/0691 ,  A61L2300/602 ,  A61L2300/62 ,  C12N2533/40

Abstract: Provided herein is a drug delivery device and composition, such as a particle, comprising conditioned medium. Also provided herein is a method of preparing polymeric particles for release of conditioned medium. Further, a tissue growth scaffold comprising particles for release of conditioned medium is provided.